Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 24Neoplasm Metastasis 11Skin Neoplasms 10Neoplasms 8Kidney Neoplasms 6Carcinoma, Renal Cell 4Breast Neoplasms 4Uveal Melanoma 3Lymphoma, Non-Hodgkin 3Uterine Cervical Neoplasms 2Rectal Neoplasms 2Neuroblastoma 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2HIV Infections 2Gastrointestinal Neoplasms 2Eye Neoplasms 2Colonic Neoplasms 2Burkitt Lymphoma 2Acquired Immunodeficiency Syndrome 2Vulvar Neoplasms 1Vulvar Diseases 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1

Interventions

Gemcitabine 54Specimen Handling 16Fluorouracil 15Radiotherapy 13Biopsy 12Oxaliplatin 10Magnetic Resonance Spectroscopy 10Erlotinib Hydrochloride 10Cyclophosphamide 10aldesleukin 8fludarabine 7Bevacizumab 7sargramostim 6Radiation 6veliparib 5Trastuzumab 5Leucovorin 5Cetuximab 5Capecitabine 5Taxes 4Sunitinib 4Irinotecan 4HhAntag691 4Cisplatin 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4tipifarnib 3rubitecan 3entinostat 3X-Rays 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pancreatic Neoplasms × Interleukin-2 × Clear all
NCT03745326 2026-05-19

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡